PTEN, a tumour suppressor, also regulates T cell activation. A new study reports that PTEN acts as a cell-intrinsic rheostat linking TCR- and IL-23-mediated signalling to regulate development of type-17 innate-like T cells in the thymus. This work may have important implications for treating autoimmune and inflammatory diseases.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vazquez, F. & Sellers, W. R. Biochim. Biophys. Acta 1470, M21–M35 (2000).
Suzuki, A. et al. Immunity 14, 523–534 (2001).
Hagenbeek, T. J. & Spits, H. Leukemia 22, 608–619 (2008).
Yehia, L., Keel, E. & Eng, C. Annu. Rev. Med. 71, 103–116 (2020).
Michelson, D. A., Hase, K., Kaisho, T., Benoist, C. & Mathis, D. Cell 185, 2542–2558 e2518 (2022).
Pellicci, D. G., Koay, H. F. & Berzins, S. P. Nat. Rev. Immunol. 20, 756–770 (2020).
Bastardo Blanco, D. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-022-01011-w (2022).
Veldhoen, M. Nat. Immunol. 18, 612–621 (2017).
Tuttle, K. D. et al. Nat. Commun. 9, 2650 (2018).
Laine, A. et al. J. Immunol. 195, 1791–1803 (2015).
Scharping, N. E. et al. Immunity 45, 374–388 (2016).
Saravia, J., Chapman, N. M. & Chi, H. Cell. Mol. Immunol. 16, 634–643 (2019).
Yang, X. O. et al. J. Biol. Chem. 282, 9358–9363 (2007).
Shi, L. Z. et al. J. Exp. Med. 208, 1367–1376 (2011).
Acknowledgements
This work was supported by US National Institutes of Health (NIH) grants R01CA238263, R01CA229784 and R01CA212605 (V.A.B.) and by grants from JDRF (International 1-INO-2002-1119-A-N) and Sanofi (iAwards SRA 2020-0033) (N.P.).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
V.A.B. has patents on the PD-1 pathway licensed by Bristol-Myers Squibb, Roche, Merck, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis and Dako. The authors declare no other competing interests.
Rights and permissions
About this article
Cite this article
Patsoukis, N., Boussiotis, V.A. PTEN checkMAITs type-17 innate-like T cells. Nat Cell Biol 24, 1565–1567 (2022). https://doi.org/10.1038/s41556-022-01012-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41556-022-01012-9
